Similarly, other studies have clarified that the application of anti-TNF-α antibodies can delay disease onset and lead to disease presentation as only mild muscle weakness [24], and we thus hypothesize that serum IL-36 is involved in the pathogenesis of MG through the interaction of these factors. Here, TNF is linked to myasthenia gravis.